

TEPADINA - (15MG, 100MG)

Generic Name	THIOTEPA	Innovator	None
Dosage	15MG, 100MG	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	TEPADINA (thiotepa) is an alkylating drug indicated: ? To reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia. ? For treatment of adenocarcinoma of the breast or ovary. ? For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. ? For treatment of superficial papillary carcinoma of the urinary bladder.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.